Careteq’s EGM Could Force a Reversal as Smart Money Folds and Insiders Stay Away

Careteq's latest capital raise is a textbook case of smart money exiting while insiders are forced to buy in. The company just completed a $2.2 million placement, issuing 440 million new shares at a price of $0.005 each. That's a 50% discount to its recent trading value, a staggering 49.96% discount to the 15-day VWAP. For context, that's a 28.57% discount to the closing price just a week before the raise. This isn't a premium placement; it's a fire sale priced to move shares, even if it means massive dilution.

The mechanics of the deal are a red flag. The raise was unbrokered, meaning no investment bank stepped in to provide a valuation or a buyer's guarantee. Instead, the advisors get a 6% fee plus GST on the funds raised, plus a sweetener: Careteq will issue 50 million options to them at a strike price of $0.015. That's a direct transfer of future equity to the dealmakers, adding another layer of dilution on top of the 440 million new shares. It's a classic "whale wallet" move where the insiders get paid to facilitate the raise, while the existing shareholders see their stakes shrink.

The most telling signal, however, came just before this capital call. In a stark reversal, a major holder, DMX Asset Management Limited, sold 33 million shares and ceased to be a substantial shareholder. This isn't a minor adjustment; it's a major player walking away. When a significant institutional investor exits a company right before it raises capital at a deep discount, it raises a fundamental question: why are they selling into a deal that's priced to fail for them? The smart money is clearly not buying in. They're taking their chips off the table, leaving the new shares to be bought by those who may not have the same skin in the game.

Insider Skin in the Game: A Look at the Board

The capital raise and the institutional exit tell one story. The board's compensation tells another. When leadership's interests are not visibly aligned with those of remaining shareholders, it's a classic sign of weak skin in the game.

The numbers here are telling. The Executive Chairman's total compensation for the last fiscal year was $222,000. That's a modest sum for a CEO, but the real signal is in the options. He exercised no stock options during that period. For the CFO and Company Secretary, the picture is even starker: no disclosed compensation or options exercised was reported. This isn't a leadership team betting its own money on the company's future. It's a team collecting a paycheck while the share price is being diluted.

Compare that to the recent actions. There has been no recent insider buying reported. The only significant movement has been the institutional exit and the massive share issuance. When the board is paid a flat fee and takes no equity risk, while the company sells shares at a 50% discount to create a new, cheaper stock, the alignment is clear: the insiders are not on the hook for the dilution. Their pay is secure regardless of what happens to the share price.

The bottom line is a lack of skin in the game. The board is not investing its own capital into the company, nor is it taking on the financial risk that comes with a major capital raise. The smart money is already leaving, and the insiders are not stepping in to buy the shares they are diluting. That's a red flag for any investor.

Catalysts and Risks: What to Watch for the Thesis

The smart money exit narrative now faces its first real test. The critical catalyst is the Extraordinary General Meeting (EGM) scheduled for 23 April 2026. This meeting must approve the second tranche of the dilutive placement, which would issue another 401 million shares at the same $0.005 price. The thesis hinges on whether the institutional and insider sentiment that led to the DMX exit holds firm, or if a reversal is coming.

Watch the EGM proceedings for any signs of new institutional accumulation or, more tellingly, insider buying. The absence of recent insider purchases is a glaring red flag. If the board or key executives step in to buy shares at this deeply discounted price, it would signal a rare alignment of interest. But given their minimal skin in the game and the unbrokered nature of the deal, that seems unlikely. The real signal will be who shows up to vote and whether any new whale wallets emerge to support the second tranche.

The post-EGM price action will be the ultimate arbiter. Once shareholder approval is secured and the new shares settle, the stock will face a clear arbitrage risk. The 50% discount to the 15-day VWAP creates a built-in incentive for traders to buy the cheap new shares and sell the existing ones. A sharp pop in the share price after settlement would confirm the market sees the dilution as a temporary overhang. A continued slide, however, would validate the smart money's skepticism and suggest the company's fundamentals or growth story are not compelling enough to attract fresh capital.

The bottom line is that the EGM is the next major data point. It will show if the smart money stays out or if a new wave of buyers steps in to absorb the flood of new shares. For now, the pattern is clear: major holders are exiting, insiders are not buying, and the company is selling at a steep discount. The coming weeks will tell us if that trend is about to reverse.